论文部分内容阅读
目的:观察芒果苷对哮喘小鼠气道炎症的影响,探讨芒果苷平喘的作用机制。方法:将72只4～5周SPF级BALB/c雌性小鼠随机分为正常对照组、模型对照组、地塞米松阳性对照组(0.001 25 g·kg-1)、芒果苷高、中、低剂量组(0.4,0.2,0.1 g·kg-1)。采用卵白蛋白(OVA)致敏和激发构建小鼠哮喘模型,收集支气管肺泡灌洗液(BALF)进行细胞计数及分类;肺组织病理切片HE染色观察炎性细胞浸润情况;采用ELISA法检测小鼠血清中OVA特异性IgE(OVA-sIgE)和BALF中白三烯C4(LTC4),前列腺素D2(PGD2)的含量。结果:芒果苷高、中、低剂量组BALF中嗜酸性粒细胞(EOS)比例由模型组(6.57±1.44)%降低为(1.63±0.43,2.72±0.83,4.11±1.08)%(P<0.01～P<0.05);芒果苷高、中剂量组BALF中白细胞总数由模型组(83.25±10.19)×105/mL减少为(25.66±6.16,53.38±9.19)×105/mL(P<0.01);芒果苷各剂量均可不同程度的改善肺组织的病理学改变,减轻气道炎症;芒果苷高、中、低剂量组血清中OVA-sIgE含量由模型组(0.26±0.04)ng·mL-1降低为(0.10±0.04,0.12±0.02,0.18±0.03)ng·mL-1(P<0.01);芒果苷高剂量组BALF中PGD2水平由模型组(74.36±22.72)ng·mL-1降低为(60.30±12.19)ng·mL-1(P<0.05),而芒果苷中、低剂量组对PGD2的降低无统计学差异;芒果苷各剂量对LTC4水平有降低趋势。结论:芒果苷可通过减少EOS浸润、小鼠体内OVA-sIgE和PGD2含量,抑制哮喘小鼠的气道炎症,在治疗哮喘方面有潜在的应用前景。
Objective: To observe the effect of mangiferin on airway inflammation in asthmatic mice and explore the mechanism of anti-asthma effect of mangiferin. Methods: Seventy-two SPF BALB / c female mice aged 4-5 weeks were randomly divided into normal control group, model control group, dexamethasone positive control group (0.001 25 g · kg -1), high, Low-dose group (0.4,0.2,0.1 g · kg-1). The asthma model was induced by ovalbumin (OVA) sensitization and challenge, and the bronchoalveolar lavage fluid (BALF) was collected for cell counting and classification. The inflammatory cell infiltration was observed by HE staining in lung tissue sections. The levels of OVA-specific IgE (OVA-sIgE) and leukotriene C4 (LTC4), prostaglandin D2 (PGD2) in BALF were determined. Results: The ratio of eosinophils (EOS) in BALF of high, medium and low doses of mangiferin decreased from (6.57 ± 1.44)% to (1.63 ± 0.43, 2.72 ± 0.83, 4.11 ± 1.08)% ~ (P <0.05). The total number of leukocytes in the BALF of mangiferin group was decreased from (83.25 ± 10.19) × 105 / mL to (25.66 ± 6.16, 53.38 ± 9.19) × 105 / mL, The levels of OVA-sIgE in mangiferin high, middle and low dose groups were significantly increased from 0.26 ± 0.04 ng · mL -1 in model group (P <0.05) (0.10 ± 0.04,0.12 ± 0.02,0.18 ± 0.03) ng · mL-1 (P <0.01). The level of PGD2 in BALF of high-dose mangiferin group decreased from 74.36 ± 22.72 ng · mL-1 to (60.30 ± 12.19) ng · mL-1 (P <0.05), while there was no significant difference in the PGD2 level between the medium and low doses of mangiferin. The levels of LTC4 in each dose of mangiferin tended to decrease. Conclusion: Mangiferin has potential application in the treatment of asthma by reducing the EOS infiltration, the content of OVA-sIgE and PGD2 in mice and inhibiting airway inflammation in asthmatic mice.